Investigating how androgen signaling affects prostate cancer growth and treatment.
Official title: Androgen signaling and sterol metabolism in metastatic prostate cancer: Functional and therapeutic implication
Funded at Cleveland State University · NIH-10201013 · Data updated 2026-11-12
This study is looking at how certain molecules in the body affect the growth of advanced prostate cancer that doesn't respond to usual treatments, with the hope of finding new ways to help patients feel better and live longer.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland State University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | August 1, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2021 |
| Award (this year) | $412,416 |
| NIH project number | 1R15CA252997-01A1 |
| Project ID | NIH-10201013 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic prostate cancer, particularly those whose cancer has become resistant to androgen-targeting therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not undergone androgen-targeting treatments may not benefit from this research.
What this research studies
This research focuses on understanding the role of androgen signaling and sterol metabolism in metastatic prostate cancer, particularly in cases that have become resistant to standard treatments. The study aims to explore how certain microRNAs can regulate key factors involved in cancer progression, specifically targeting the androgen receptor and sterol regulatory elements. By examining these molecular mechanisms, the research seeks to identify new therapeutic strategies that could improve treatment outcomes for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with castration-resistant prostate cancer.
How similar studies have gone: Previous research has shown promising results in targeting androgen signaling pathways in prostate cancer, indicating that this approach could be effective.
Where this research is happening
-
Cleveland State University
Cleveland, United States Active
Researchers
- Principal investigator: Shukla, Girish C — Cleveland State University
- Study coordinator: Shukla, Girish C
Related research
Other NIH-funded projects on the same topics.
-
Combination immunotherapy with radioligand therapy for metastatic prostate cancer
A study aims to help men with advanced prostate cancer by combining immune therapy with targeted radiation to boost the body’s own defense against cancer.
-
Understanding what drives lethal metastatic prostate cancer in men
This grant looks at why some prostate cancers become deadly and spread, using patient-derived cells and mouse models.
-
Off-the-shelf tumor cell vaccine tailored to your tumor’s HLA type for advanced prostate cancer
A new vaccine approach uses donor cancer cells matched to a patient’s immune system to help fight advanced prostate cancer.
-
ASH1L’s role in metastatic prostate cancer and its immune environment
Aims to understand how the ASH1L gene helps prostate cancer spread and how it shapes the immune environment in bone metastases so future therapies can target this process.
-
Molecular drivers of lineage changes and new therapies for metastatic prostate cancer
A multi-year study at a major university will explore how metastatic prostate cancer changes its cell type and how to target those changes to help patients.
-
How gut bacteria may affect prostate cancer therapy and resistance
A new study looks at how gut bacteria make compounds that influence prostate cancer treatments and may drive resistance to therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.